» Articles » PMID: 38753616

Study Protocol: Close Assessment and Testing for Chronic Graft-vs.-Host Disease (CATCH)

Overview
Journal PLoS One
Date 2024 May 16
PMID 38753616
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic graft-versus-host disease (GVHD) is an immune-mediated disorder that causes significant late morbidity and mortality following allogeneic hematopoietic cell transplantation. The "Close Assessment and Testing for Chronic GVHD (CATCH)" study is a multi-center Chronic GVHD Consortium prospective, longitudinal cohort study designed to enroll patients before hematopoietic cell transplantation and follow them closely to capture the development of chronic GVHD and to identify clinical and biologic biomarkers of chronic GVHD onset. Data are collected pre-transplant and every two months through one-year post-transplant with chart review thereafter. Evaluations include clinician assessment of chronic GVHD and its manifestations, patient-reported outcomes, multiple biospecimens (blood, saliva, tears, buccal mucosa and fecal samples, biopsies of skin and mouth), laboratory testing, and medical record abstraction. This report describes the rationale, design, and methods of the CATCH study, and invites collaboration with other investigators to leverage this resource. trial registration: This study is registered at www.clinicaltrials.gov as NCT04188912.

Citing Articles

Oral and Gut Microbiome Alterations in Oral Chronic GVHD Disease: Results from Close Assessment and Testing for Chronic GVHD (CATCH Study).

Rashidi A, Pidala J, Hamilton B, Pavletic S, Kim K, Zevin A Clin Cancer Res. 2024; 30(18):4240-4250.

PMID: 39017661 PMC: 11398982. DOI: 10.1158/1078-0432.CCR-24-0875.

References
1.
Merkel E, Mitchell S, Lee S . Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews. Biol Blood Marrow Transplant. 2016; 22(4):752-758. PMC: 4850024. DOI: 10.1016/j.bbmt.2015.12.026. View

2.
Basch E, Reeve B, Mitchell S, Clauser S, Minasian L, Dueck A . Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014; 106(9). PMC: 4200059. DOI: 10.1093/jnci/dju244. View

3.
Zeiser R, Lee S . Three US Food and Drug Administration-approved therapies for chronic GVHD. Blood. 2022; 139(11):1642-1645. PMC: 8931512. DOI: 10.1182/blood.2021014448. View

4.
Inamoto Y, Flowers M, Lee S, Carpenter P, Warren E, Deeg H . Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood. 2011; 118(2):456-63. PMC: 3138695. DOI: 10.1182/blood-2011-01-330217. View

5.
Lee S, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M . Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015; 21(6):984-99. PMC: 4744804. DOI: 10.1016/j.bbmt.2015.02.025. View